Developer docs
API playgroundTry for free, no card

Search company profiles

Intuitive Investments Group

Full company profile

uuid00043v6

Namestring
Intuitive Investments Group
Legal namestring
Intuitive Investments Group plc
Websiteurl
iigplc.com
Company typeenum
Public
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
life science investing, venture capital, biotech investments, healthcare investment, investment holding
Industry4 codes
1Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryYes
2Equity Capital Advisory (Private Equity Placements, Growth Capital)
CodeBPAHAOAEPrimaryNo
3Capital Raising Advisory (Equity & Equity-Linked)
CodeFSAEAGACPrimaryNo
4Institutional Capital Introduction (LP/Family Office/Endowment Matching)
CodeFSAEALAIPrimaryNo
NAICS code4 codes
  • Portfolio Management and Investment Advice523940
  • All Other Financial Investment Activities52399
  • Other Financial Investment Activities5239
  • Other Investment Pools and Funds5259
SIC code2 codes
  • Investment Advice6282
  • Investors, Nec6799
Product category
Life Science Investment
No data
Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Intuitive Investments Group plc offers investment into life science companies, deploying capital into operating businesses in the life sciences sector for the purpose of generating investment returns. The firm functions as a publicly listed investment vehicle focused on the life sciences vertical, with its shares trading on the London Stock Exchange under ticker IIG.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Life Science Investment Programme
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Octopus Titan VCT
TypeEmerging player
Description

Octopus Titan VCT is a UK venture capital trust investing in early-stage UK companies including life sciences — a partial overlap with IIG's early-stage life sciences investment mandate through a different listed vehicle type.

2Syncona Limited
TypeDirect peer
Description

Syncona (LSE: SYNC) is a UK-listed investment company that builds and funds life sciences businesses — a direct strategic peer to IIG in mandate, geography, and listed-vehicle structure.

3Arix Bioscience
TypeDirect peer
Description

Arix is a London-listed life sciences investment company focused on developing and financing breakthrough biotech companies — directly comparable to IIG in sector and listed investment-vehicle form.

4IP Group plc
TypeDirect peer
Description

IP Group (LSE: IPO) is a UK-listed IP commercialisation company that invests in and builds deep-tech and life sciences businesses from university research — a comparable listed science-investment vehicle.

5RTW Investments
TypeDirect peer
Description

RTW Investments is a New York-based specialist life sciences and healthcare investment manager with both private and listed fund vehicles — directly comparable in sector specialism and cross-format investment approach.

6Worldwide Healthcare Trust
TypeDirect peer
Description

Worldwide Healthcare Trust is a London-listed investment trust focused on healthcare and biotechnology equities — a comparable listed vehicle with concentrated healthcare exposure, though at the quoted-equity level rather than private.

7Polar Capital Global Healthcare
TypeBroad incumbent
Description

Polar Capital Global Healthcare Trust is an established London-listed healthcare-focused investment trust — a broader incumbent with overlapping sector exposure but a quoted-equities mandate rather than private life sciences investing.

8BB Biotech
TypeBroad incumbent
Description

BB Biotech is a Swiss-listed investment company with a long-standing biotech mandate — a broad incumbent operating in the same listed-biotech-investment category as IIG, though at significantly greater scale.

9Allied Minds plc
TypeEmerging player
Description

Allied Minds is a US/UK technology and life sciences IP commercialisation and investment company — an emerging/early-stage player with comparable sector exposure and listed-vehicle structure to IIG.

10Chrysalis Investments
TypeOthers
Description

Chrysalis Investments is a London-listed investment company — thematically related as a UK-listed investment vehicle, though with a different (primarily growth-equity) mandate rather than life sciences focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intuitive Investments Group

Life Science Investmentiigplc.com

Intuitive Investments Group firmographics

Firmographics
Name
Intuitive Investments Group
Legal name
Intuitive Investments Group plc
Website
https://iigplc.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Intuitive Investments Group industry classification

Industry
Product category
Life Science Investment
NAICS
Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399), Other Financial Investment Activities (5239), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282), Investors, Nec (6799)
akta.pro primary industry
Healthcare & Life Sciences Growth Equity (FSANACAB)
akta.pro secondary industries
Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC), Institutional Capital Introduction (LP/Family Office/Endowment Matching) (FSAEALAI)

Keywords

  • Life science investing
  • Venture capital
  • Biotech investments
  • Healthcare investment
  • Investment holding

Where Intuitive Investments Group is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Intuitive Investments Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Intuitive Investments Group product offering

Product offering

Core offering

Intuitive Investments Group plc offers investment into life science companies, deploying capital into operating businesses in the life sciences sector for the purpose of generating investment returns. The firm functions as a publicly listed investment vehicle focused on the life sciences vertical, with its shares trading on the London Stock Exchange under ticker IIG.

Differentiator

Problem solved

Functional benefit

Products and services

  • Life Science Investment Programme

Companies that use Intuitive Investments Group

Customer profile

Ideal customer profiles2 records

Intuitive Investments Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Intuitive Investments Group partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Intuitive Investments Group competitors and assessment

Company assessment

Emerging players

  • Octopus Titan VCT: Octopus Titan VCT is a UK venture capital trust investing in early-stage UK companies including life sciences — a partial overlap with IIG's early-stage life sciences investment mandate through a different listed vehicle type.
  • Allied Minds plc: Allied Minds is a US/UK technology and life sciences IP commercialisation and investment company — an emerging/early-stage player with comparable sector exposure and listed-vehicle structure to IIG.

Direct peers

  • Syncona Limited: Syncona (LSE: SYNC) is a UK-listed investment company that builds and funds life sciences businesses — a direct strategic peer to IIG in mandate, geography, and listed-vehicle structure.
  • Arix Bioscience: Arix is a London-listed life sciences investment company focused on developing and financing breakthrough biotech companies — directly comparable to IIG in sector and listed investment-vehicle form.
  • IP Group plc: IP Group (LSE: IPO) is a UK-listed IP commercialisation company that invests in and builds deep-tech and life sciences businesses from university research — a comparable listed science-investment vehicle.
  • RTW Investments: RTW Investments is a New York-based specialist life sciences and healthcare investment manager with both private and listed fund vehicles — directly comparable in sector specialism and cross-format investment approach.
  • Worldwide Healthcare Trust: Worldwide Healthcare Trust is a London-listed investment trust focused on healthcare and biotechnology equities — a comparable listed vehicle with concentrated healthcare exposure, though at the quoted-equity level rather than private.

Broad incumbents

  • Polar Capital Global Healthcare: Polar Capital Global Healthcare Trust is an established London-listed healthcare-focused investment trust — a broader incumbent with overlapping sector exposure but a quoted-equities mandate rather than private life sciences investing.
  • BB Biotech: BB Biotech is a Swiss-listed investment company with a long-standing biotech mandate — a broad incumbent operating in the same listed-biotech-investment category as IIG, though at significantly greater scale.

Others

  • Chrysalis Investments: Chrysalis Investments is a London-listed investment company — thematically related as a UK-listed investment vehicle, though with a different (primarily growth-equity) mandate rather than life sciences focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Intuitive Investments Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intuitive Investments Group leadership team

Management profile

Number of profiles

Profiles1 record

Intuitive Investments Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intuitive Investments Group M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intuitive Investments Group

What does Intuitive Investments Group do?

Intuitive Investments Group plc offers investment into life science companies, deploying capital into operating businesses in the life sciences sector for the purpose of generating investment returns. The firm functions as a publicly listed investment vehicle focused on the life sciences vertical, with its shares trading on the London Stock Exchange under ticker IIG.

Is Intuitive Investments Group a public or private company?

Intuitive Investments Group is a public company. It is classified as public and is currently operating.

When was Intuitive Investments Group founded?

Intuitive Investments Group was founded in 2020. It employs 1 to 10 people.

Where is Intuitive Investments Group based?

Intuitive Investments Group is headquartered in London, United Kingdom, in the Europe region.

Who are Intuitive Investments Group's main competitors?

Emerging players on record are Octopus Titan VCT and Allied Minds plc. Direct peers are Syncona Limited, Arix Bioscience, IP Group plc, RTW Investments and Worldwide Healthcare Trust. Broad incumbents are Polar Capital Global Healthcare and BB Biotech. Chrysalis Investments is listed as an others.

Does Intuitive Investments Group have an API?

No public API is recorded for Intuitive Investments Group.

What industry is Intuitive Investments Group in?

Intuitive Investments Group's product category is Life Science Investment. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NortonrosefulbrightNorton Rose Fulbright advises Berenberg on £600 million acquisition of Intuitive Investments Group plcNorton Rose Fulbright advised Berenberg on Acceler8 Ventures' £600 million acquisition of Intuitive Investments Group, a reverse takeover that admitted the enlarged group to trading on the London Stock Exchange. The transaction centers on IIG's principal asset, Hui10, a Beijing-headquartered technology group supporting China's regulated lottery ecosystem. This cross-border deal was executed via a court-sanctioned scheme of arrangement under UK Listing Rules.InvestegateCancellation - Intuitive Investments Group plcIntuitive Investments Group plc has had its ordinary shares cancelled from admission to trading on the London Stock Exchange, effective from 14 August 2026 at 08:00. This delisting was initiated at the company's own request.InvestegateAdmission to ESCC & Adviser AppointmentAcceler8 Ventures Plc has admitted its entire issued share capital to the Official List of the FCA and began trading on the London Stock Exchange's Main Market under the ticker 'AC8'. This admission follows an all-share acquisition of Intuitive Investments Group plc, positioning the enlarged group with principal operations in Chinese technology group Hui10 Inc. Joh. Berenberg, Gossler & Co KG has been appointed as the sole corporate broker and financial adviser for the transaction.FinanzNachrichten.deXFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.08.2026Boerse Frankfurt announced that several financial instruments, including those from Fresenius SE & Co. KGaA and Intuitive Investment Group, will have their last trading day on August 12, 2026. This deletion removes these specific securities from the exchange's listing. The move represents a routine administrative update regarding the delisting of these particular assets.AdvfnIntuitive Investments Group plc Court Sanction of the SchemeAcceler8 Ventures Plc announced court approval of its scheme to acquire all shares of Intuitive Investments Group plc, with the scheme expected to become effective on 13 August 2026. The acquisition will be implemented through a court-sanctioned scheme under UK law, and subsequent trading and shareholder meetings are scheduled accordingly.AdvfnIntuitive Investments Group plc Results of the Court Meeting and General MeetingAcceler8 Ventures Plc announced that shareholders of Intuitive Investments Group plc voted overwhelmingly in favor of the recommended all-share acquisition, with 94.87% of Scheme Shareholders approving at the Court Meeting and 99.99% approving at the General Meeting, representing approximately 68-70% of eligible voting shares. The acquisition remains subject to Court sanction at the hearing on 6 August 2026, delivery of the Court Order to the Registrar of Companies, and other outstanding conditions, with the effective date expected on 13 August 2026. Upon completion, AC8 Shares will be admitted to trading on the London Stock Exchange's Main Market under the ESCC category.Investing.comhttps://in.investing.com/news/stock-market-news/intuitive-investments-extends-takeover-deadline-to-july-1-93CH-5437961Intuitive Investments Group plc announced that the deadline for Acceler8 Ventures plc to make a firm takeover offer has been extended to July 1, 2026. The companies are still in discussions about a possible all-share offer, and preparations including due diligence continue.Investing.comIntuitive Investments extends takeover deadline to July 1 By Investing.comIntuitive Investments Group plc announced that the deadline for Acceler8 Ventures plc to make a firm takeover offer has been extended to July 1, 2026, with consent from the Takeover Panel at the request of Intuitive Investments' independent directors. The possible all-share offer would transfer the entire issued share capital of Intuitive Investments to Acceler8, with the combined entity seeking admission to the Official List and trading on the London Stock Exchange main market. The article notes there is no certainty the offer will ultimately be made, as due diligence and prospectus preparation continue between the parties.AdvfnIN BRIEF: Intuitive Investments raises GBP1.6 million to advance Hui10Intuitive Investments Group Plc raised GBP1.6 million through a share issue to advance its Hui10 project. The company is based in Manchester, England, and operates in life sciences and technology investment.